Poseida Therapeutics, Inc. (PSTX)

NASDAQ: PSTX · IEX Real-Time Price · USD
7.35
+0.03 (0.41%)
At close: Jan 27, 2023, 4:00 PM
7.71
+0.36 (4.88%)
After-hours: Jan 27, 2023, 5:41 PM EST
0.41%
Market Cap 631.73M
Revenue (ttm) 151.68M
Net Income (ttm) -29.22M
Shares Out 85.95M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 268,019
Open 7.32
Previous Close 7.32
Day's Range 7.16 - 7.47
52-Week Range 1.82 - 7.64
Beta 0.12
Analysts Buy
Price Target 15.10 (+105.44%)
Earnings Date Mar 9, 2023

About PSTX

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Eric Ostertag
Employees 304
Stock Exchange NASDAQ
Ticker Symbol PSTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for PSTX stock is "Buy." The 12-month stock price forecast is $15.1, which is an increase of 105.44% from the latest price.

Price Target
$15.1
(105.44% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Poseida Therapeutics, Inc. (PSTX) is on the Move, Here's Why the Trend Could be Sustainable

Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that m...

14 hours ago - Zacks Investment Research

Recent Price Trend in Poseida Therapeutics, Inc. (PSTX) is Your Friend, Here's Why

Poseida Therapeutics, Inc. (PSTX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that m...

2 weeks ago - Zacks Investment Research

Poseida Therapeutics, Inc. (PSTX) Is a Great Choice for 'Trend' Investors, Here's Why

Poseida Therapeutics, Inc. (PSTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

1 month ago - Zacks Investment Research

Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition

Data demonstrate that a non-viral, liver-directed gene therapy utilizing Super piggyBac® (SPB) DNA Modification System achieved and maintained normalized human FVIII (hFVIII) activity following a sing...

1 month ago - PRNewsWire

Wall Street Analysts See an 189% Upside in Poseida Therapeutics, Inc. (PSTX): Can the Stock Really Move This High?

The mean of analysts' price targets for Poseida Therapeutics, Inc. (PSTX) points to an 189.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agr...

1 month ago - Zacks Investment Research

Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress

P-MUC1C-ALLO1 and P-BCMA-ALLO1 were well tolerated, with no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), graft vs host disease (GVHD) or immune effector cell-associated neurotoxic...

1 month ago - PRNewsWire

Poseida Therapeutics, Inc. (PSTX) Tops Q3 Earnings and Revenue Estimates

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 235.29% and 5,715.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead fo...

2 months ago - Zacks Investment Research

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022

Entered into a strategic collaboration with Roche to develop allogeneic CAR-T cell therapies for hematological indications; received $110 million upfront payment and achieved the first clinical milest...

2 months ago - PRNewsWire

Poseida Therapeutics to Present at Two Upcoming Investor Conferences

SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create...

2 months ago - PRNewsWire

Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition

Preclinical data to be presented highlight sustained and normalized Factor VIII activity following single dose of P-FVIII-101 for the treatment of Hemophilia A SAN DIEGO , Nov. 3, 2022 /PRNewswire/ --...

3 months ago - PRNewsWire

Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual Congress

SAN DIEGO , Nov. 3, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create...

3 months ago - PRNewsWire

Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting

SAN DIEGO , Oct. 5, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create...

4 months ago - PRNewsWire

Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

SAN DIEGO , Sept. 7, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to creat...

5 months ago - PRNewsWire

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022

Announced strategic collaboration with Roche, with a $110 million upfront payment, to focus on the research and development of allogeneic CAR-T cell therapies directed to hematologic malignancies Comp...

6 months ago - PRNewsWire

Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO , Aug. 8, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create...

6 months ago - PRNewsWire

Poseida Therapeutics Announces Pricing of Public Offering of Common Stock

SAN DIEGO , Aug. 4, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create...

6 months ago - PRNewsWire

Poseida Therapeutics (PSTX) Stock Rockets 79% on Roche Deal

Source: Shutterstock Poseida Therapeutics (NASDAQ: PSTX) stock is soaring on Wednesday after the clinical-stage biotechnology company announced a deal with Roche (OTCMKTS: RHHBY). The agreement with...

Other symbols: RHHBY
6 months ago - InvestorPlace

Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies

Leveraging Poseida's novel approach to cell therapy and Roche's expertise in developing and commercializing therapies to transform cancer care, the collaboration is focused on advancing multiple exist...

6 months ago - PRNewsWire

Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board

SAN DIEGO , July 26, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to creat...

6 months ago - PRNewsWire

Poseida Therapeutics Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products

Publication highlights ability of Cas-CLOVER to perform multiplexed gene editing to produce allogeneic products with a high percentage of Tscm cells that may result in better tolerability and deeper c...

7 months ago - PRNewsWire

Poseida Therapeutics Announces Virtual 2022 Annual Meeting of Stockholders

SAN DIEGO , June 2, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create...

8 months ago - PRNewsWire

Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting

Preclinical data supports potential of P-ckit-ALLO1 as a less toxic preconditioning agent for hematopoietic stem cell (HSC) transplants P-ckit-ALLO1 eliminates >95% of hematopoietic stem and progenito...

9 months ago - PRNewsWire

Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Misses Revenue Estimates

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -60.34% and 42.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s...

9 months ago - Zacks Investment Research

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2022

SAN DIEGO , May 12, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create...

9 months ago - PRNewsWire

Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting

Preclinical data to be presented supports potential of anti-c-kit CAR-T cells as a highly specific and less toxic conditioning regimen for hematopoietic stem cell transplantation SAN DIEGO , May 2, 20...

9 months ago - PRNewsWire